Literature DB >> 30062384

Minimizing the Risk of Perinatal Human Immunodeficiency Virus Transmission.

Matthew Givens1, Sarah K Dotters-Katz2, Elizabeth Stringer3, Lisa Rahangdale4, Jeffrey A Kuller5.   

Abstract

IMPORTANCE: There are approximately 284,500 adolescent and adult women living with human immunodeficiency virus (HIV) in the United States. It is estimated that approximately 8500 of these women give birth annually. While the rate of perinatal transmission in the United States has decreased by more than 90% since the early 1990s, potentially preventable HIV transmission events still occur and cause significant morbidity and mortality.
OBJECTIVE: The aim of this review was to summarize the current data regarding perinatal HIV transmission timing and risk factors, current management recommendations, and implications of timing of transmission on patient management. EVIDENCE ACQUISITION: Literature review.
RESULTS: This review reiterates that the risk of perinatal HIV transmission can be reduced to very low levels by following current recommendations for screening for HIV in all pregnant women and properly treating HIV-infected mothers, as well as using evidence-based labor management practices. CONCLUSIONS AND RELEVANCE: Familiarity with the pathogenesis of HIV transmission is important for obstetric care providers to appropriately manage HIV-infected women in pregnancy, intrapartum, and the postpartum period.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30062384     DOI: 10.1097/OGX.0000000000000581

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  2 in total

Review 1.  Controversies in Breastfeeding.

Authors:  Riccardo Davanzo
Journal:  Front Pediatr       Date:  2018-11-01       Impact factor: 3.418

2.  HIV-1 mother-to-child transmission in Brazil (1994-2016): a time series modeling.

Authors:  Antonio Victor Campos Coelho; Hemílio Fernandes Campos Coelho; Luiz Cláudio Arraes; Sergio Crovella
Journal:  Braz J Infect Dis       Date:  2019-07-22       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.